Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free VMD Stock Alerts

Viemed Healthcare (VMD) Competitors

Viemed Healthcare logo
$8.82 +0.02 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$8.82 -0.01 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VMD vs. AMN, OMDA, OPK, CSTL, and LMRI

Should you buy Viemed Healthcare stock or one of its competitors? Viemed Healthcare's main competitors and comparable companies include AMN Healthcare Services (AMN), Omada Health (OMDA), OPKO Health (OPK), Castle Biosciences (CSTL), and Lumexa Imaging (LMRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Viemed Healthcare compare to AMN Healthcare Services?

Viemed Healthcare (NASDAQ:VMD) and AMN Healthcare Services (NYSE:AMN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AMN Healthcare Services had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 3 mentions for AMN Healthcare Services and 1 mentions for Viemed Healthcare. AMN Healthcare Services' average media sentiment score of 0.88 beat Viemed Healthcare's score of 0.00 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company Overall Sentiment
Viemed Healthcare Neutral
AMN Healthcare Services Positive

Viemed Healthcare has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$270.28M1.24$14.93M$0.3624.50
AMN Healthcare Services$2.73B0.49-$95.70M$2.6812.92

Viemed Healthcare presently has a consensus price target of $14.00, indicating a potential upside of 58.73%. AMN Healthcare Services has a consensus price target of $36.00, indicating a potential upside of 4.01%. Given Viemed Healthcare's higher probable upside, research analysts clearly believe Viemed Healthcare is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
AMN Healthcare Services
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Viemed Healthcare has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Viemed Healthcare has a net margin of 4.81% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Viemed Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare4.81% 10.16% 7.22%
AMN Healthcare Services 3.06%19.92%5.93%

Summary

Viemed Healthcare and AMN Healthcare Services tied by winning 8 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to Omada Health?

Omada Health (NASDAQ:OMDA) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Viemed Healthcare has higher revenue and earnings than Omada Health. Viemed Healthcare is trading at a lower price-to-earnings ratio than Omada Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omada Health$260.21M4.64-$12.78M$0.05394.40
Viemed Healthcare$270.28M1.24$14.93M$0.3624.50

In the previous week, Omada Health had 4 more articles in the media than Viemed Healthcare. MarketBeat recorded 5 mentions for Omada Health and 1 mentions for Viemed Healthcare. Omada Health's average media sentiment score of 1.44 beat Viemed Healthcare's score of 0.00 indicating that Omada Health is being referred to more favorably in the media.

Company Overall Sentiment
Omada Health Positive
Viemed Healthcare Neutral

Omada Health has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Omada Health presently has a consensus target price of $26.67, suggesting a potential upside of 35.23%. Viemed Healthcare has a consensus target price of $14.00, suggesting a potential upside of 58.73%. Given Viemed Healthcare's higher possible upside, analysts plainly believe Viemed Healthcare is more favorable than Omada Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omada Health
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
Viemed Healthcare
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

74.2% of Viemed Healthcare shares are owned by institutional investors. 6.4% of Omada Health shares are owned by insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Viemed Healthcare has a net margin of 4.81% compared to Omada Health's net margin of 1.39%. Viemed Healthcare's return on equity of 10.16% beat Omada Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Omada Health1.39% 2.60% 1.98%
Viemed Healthcare 4.81%10.16%7.22%

Summary

Viemed Healthcare beats Omada Health on 9 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Viemed Healthcare has a net margin of 4.81% compared to OPKO Health's net margin of -12.40%. Viemed Healthcare's return on equity of 10.16% beat OPKO Health's return on equity.

Company Net Margins Return on Equity Return on Assets
OPKO Health-12.40% -5.88% -3.83%
Viemed Healthcare 4.81%10.16%7.22%

OPKO Health has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

OPKO Health presently has a consensus price target of $1.55, indicating a potential downside of 5.49%. Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 58.73%. Given Viemed Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Viemed Healthcare is more favorable than OPKO Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OPKO Health
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Viemed Healthcare
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Viemed Healthcare has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OPKO Health$606.90M2.02-$225.68M-$0.09N/A
Viemed Healthcare$270.28M1.24$14.93M$0.3624.50

In the previous week, OPKO Health had 5 more articles in the media than Viemed Healthcare. MarketBeat recorded 6 mentions for OPKO Health and 1 mentions for Viemed Healthcare. OPKO Health's average media sentiment score of 0.72 beat Viemed Healthcare's score of 0.00 indicating that OPKO Health is being referred to more favorably in the media.

Company Overall Sentiment
OPKO Health Positive
Viemed Healthcare Neutral

Summary

Viemed Healthcare beats OPKO Health on 9 of the 15 factors compared between the two stocks.

How does Viemed Healthcare compare to Castle Biosciences?

Viemed Healthcare (NASDAQ:VMD) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Viemed Healthcare has a net margin of 4.81% compared to Castle Biosciences' net margin of -5.43%. Viemed Healthcare's return on equity of 10.16% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare4.81% 10.16% 7.22%
Castle Biosciences -5.43%-4.15%-3.45%

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Viemed Healthcare has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

Viemed Healthcare has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$270.28M1.24$14.93M$0.3624.50
Castle Biosciences$344.23M3.12-$24.16M-$0.66N/A

In the previous week, Castle Biosciences had 7 more articles in the media than Viemed Healthcare. MarketBeat recorded 8 mentions for Castle Biosciences and 1 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.00 beat Castle Biosciences' score of -0.05 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Viemed Healthcare Neutral
Castle Biosciences Neutral

Viemed Healthcare presently has a consensus target price of $14.00, suggesting a potential upside of 58.73%. Castle Biosciences has a consensus target price of $42.00, suggesting a potential upside of 19.35%. Given Viemed Healthcare's higher possible upside, research analysts clearly believe Viemed Healthcare is more favorable than Castle Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Viemed Healthcare beats Castle Biosciences on 10 of the 17 factors compared between the two stocks.

How does Viemed Healthcare compare to Lumexa Imaging?

Lumexa Imaging (NASDAQ:LMRI) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

74.2% of Viemed Healthcare shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Viemed Healthcare has a net margin of 4.81% compared to Lumexa Imaging's net margin of 0.00%. Viemed Healthcare's return on equity of 10.16% beat Lumexa Imaging's return on equity.

Company Net Margins Return on Equity Return on Assets
Lumexa ImagingN/A N/A N/A
Viemed Healthcare 4.81%10.16%7.22%

Lumexa Imaging presently has a consensus price target of $17.50, indicating a potential upside of 77.13%. Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 58.73%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lumexa Imaging is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lumexa Imaging
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Viemed Healthcare
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Lumexa Imaging had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 3 mentions for Lumexa Imaging and 1 mentions for Viemed Healthcare. Lumexa Imaging's average media sentiment score of 0.74 beat Viemed Healthcare's score of 0.00 indicating that Lumexa Imaging is being referred to more favorably in the media.

Company Overall Sentiment
Lumexa Imaging Positive
Viemed Healthcare Neutral

Viemed Healthcare has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lumexa Imaging$267.73M3.55-$47.10M-$0.49N/A
Viemed Healthcare$270.28M1.24$14.93M$0.3624.50

Summary

Viemed Healthcare beats Lumexa Imaging on 8 of the 15 factors compared between the two stocks.

Get Viemed Healthcare News Delivered to You Automatically

Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VMD vs. The Competition

Export
MetricViemed HealthcareHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$341.27M$9.76B$7.33B$13.29B
Dividend YieldN/A2.59%2.52%12.57%
P/E Ratio24.5028.84214.3421.27
Price / Sales1.244.96639.6687.10
Price / Cash7.78122.1177.8052.76
Price / Book2.335.1910.526.34
Net Income$14.93M$315.70M$3.49B$360.00M
7 Day Performance-1.45%-1.94%-1.08%-0.11%
1 Month Performance-2.97%-2.33%-3.39%-3.42%
1 Year Performance30.09%12.96%15.08%5.46%

Viemed Healthcare Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VMD
Viemed Healthcare
3.8001 of 5 stars		$8.82
+0.2%		$14.00
+58.7%		+30.4%$341.27M$270.28M24.501,382
AMN
AMN Healthcare Services
2.0111 of 5 stars		$34.65
+1.2%		$36.00
+3.9%		+83.8%$1.33B$2.73B12.932,664
OMDA
Omada Health
3.9446 of 5 stars		$21.37
+3.7%		$26.67
+24.8%		-11.7%$1.26B$260.21M427.40946
OPK
OPKO Health
0.9561 of 5 stars		$1.73
+2.4%		$1.55
-10.4%		+18.1%$1.26B$606.90MN/A1,373
CSTL
Castle Biosciences
2.3073 of 5 stars		$34.85
-0.4%		$42.00
+20.5%		+48.0%$1.07B$344.23MN/A1,002

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VMD) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel